RYBREVANT® in combination with carboplatin and pemetrexed (chemotherapy) extended the time people lived without cancer growing or spreading
Almost twice the time without disease progression.
At 11.4 months, half of the people treated with RYBREVANT® + chemotherapy lived without the disease getting worse, compared to 6.7 months for chemotherapy alone.
EGFR, epidermal growth factor receptor.
40% of people treated with RYBREVANT® after chemotherapy that contains platinum saw their tumors disappear (3.7%) or get smaller (36%).
EGFR, epidermal growth factor receptor.
Register for Updates
Sign up to receive the latest news and information about RYBREVANT®
